<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872608</url>
  </required_header>
  <id_info>
    <org_study_id>21-194</org_study_id>
    <nct_id>NCT04872608</nct_id>
  </id_info>
  <brief_title>A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer</brief_title>
  <official_title>ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Context Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are doing this study to find out whether the study drug onapristone ER,&#xD;
      combined with the standard treatment for your cancer (letrozole and palbociclib), is a safe&#xD;
      treatment for people who have metastatic or unresectable ER+/PR+/HER2- breast cancer. The&#xD;
      researchers will test different doses of the study drug to find the highest dose that causes&#xD;
      few or mild side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">September 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open label, single institution pilot phase 1b study of the oral progesterone antagonist, onapristone ER (Apristor), used as triplet escalation therapy patients with ER+/PR+/HER2- MBC who do not achieve mCR after six months (+/- 4 weeks) of treatment with letrozole and palbociclib in the first line.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recommended phase 2 dose (RP2D) of onapristone ER</measure>
    <time_frame>1 year</time_frame>
    <description>The RP2D/MTD will be defined as the dose level at which a dose limiting toxicity (DLT) occurs in at most 1 out of 6 patients in that dose cohort.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Unresectable Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole, Palbociclib, and Onapristone ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study has two stages: a dose-finding stage and a dose expansion stage. Stage 1 of the study will utilize a standard 3+3 dose de-escalation design with a total of three dose levels of onapristone ER, 30mg PO BID, 40mg PO BID, and 50mg PO BID given on a 28-day cycle. Onapristone ER will be given in addition to letrozole 2.5mg QD and each patient's pre-enrollment dose of palbociclib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole will be given daily on days 1-28.</description>
    <arm_group_label>Letrozole, Palbociclib, and Onapristone ER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib will be given daily on days 1-21 and held on days 22-28, as per standard FDA-approved dosing guidelines.</description>
    <arm_group_label>Letrozole, Palbociclib, and Onapristone ER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onapristone ER</intervention_name>
    <description>Onapristone will be given daily on days 1-28.</description>
    <arm_group_label>Letrozole, Palbociclib, and Onapristone ER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed ER+, PR+, HER2- metastatic or unresectable breast cancer&#xD;
&#xD;
               -  PR positivity is defined as ≥1% expression by immunohistochemistry (IHC) on fresh&#xD;
                  or archival tumor tissue&#xD;
&#xD;
               -  Tissue samples obtained, stained, and interpreted outside of MSKCC will be&#xD;
                  accepted&#xD;
&#xD;
               -  Those patients who do not have adequate/accessible archival tissue available and&#xD;
                  for whom biopsy is not a significant risk procedure may be required to consent to&#xD;
                  pretreatment biopsy&#xD;
&#xD;
          -  Completed at least 6 months (+/- 4 weeks) of first-line letrozole/palbociclib without&#xD;
             radiological progression or unresolved toxicity&#xD;
&#xD;
             °Patients who underwent dose reduction of palbociclib to 100mg daily or 75mg daily&#xD;
             will be eligible if:&#xD;
&#xD;
               1. The dose reduction was implemented ≥4 weeks prior to enrollment&#xD;
&#xD;
               2. Patients have demonstrated resolution of all acute toxic effects of prior therapy&#xD;
                  to NCI CTCAE (Version 5.0) Grade ≤ 1&#xD;
&#xD;
          -  ctDNA-positive, defined as:&#xD;
&#xD;
             °Presence of a tumor-derived somatic mutation in the peripheral blood using the&#xD;
             MSK-ACCESS assay after 6 months of letrozole/palbociclib (+/- 4 weeks); at least one&#xD;
             mutation should have avariant allele fraction of ≥ 0.5%&#xD;
&#xD;
          -  Completed MSK IMPACT testing from primary or metastatic tissue&#xD;
&#xD;
          -  Radiologically evaluable or measurable disease per RECIST Version 1.1&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Pre-menopausal patients are eligible as long as they are on LHRH agonist for at least&#xD;
             four weeks prior to starting trial therapy and commit to continue LHRH agonist for as&#xD;
             long as patient is receiving trial therapy or medical contraindications arise.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG) of 1 or Karnofsky&#xD;
             Performance Status (KPS) of ≥ 70%&#xD;
&#xD;
          -  Women of child-bearing potential:&#xD;
&#xD;
               -  Must have a negative pregnancy test within 14 days prior to commencement of study&#xD;
                  treatment&#xD;
&#xD;
               -  Agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
                  nonhormonal contraceptive methods with a failure rate of &lt;1% per year during the&#xD;
                  treatment period and for 120 days after the last dose and agreement to refrain&#xD;
                  from donating eggs during this same period&#xD;
&#xD;
               -  Note: for women with therapy-induced amenorrhea, baseline measurements of FSH&#xD;
                  and/or estradiol are needed to ensure menopausal status.&#xD;
&#xD;
          -  Adequate hematologic and organ function demonstrated within 14 days prior to&#xD;
             initiation of study treatment, defined by the following:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.2K/ µL&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Platelet count ≥ 100,000/ µL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  Serum albumin ≥ 2.5 g/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min on the basis of the&#xD;
             Cockcroft-Gault glomerular filtration rate estimation&#xD;
&#xD;
          -  INR &lt; 1.5 x ULN and aPTT &lt; 1.5 x ULN&#xD;
&#xD;
             °For patients requiring anticoagulation therapy with warfarin, a stable INR between&#xD;
             2-3 is required. If anticoagulation is required for a prosthetic heart valve, then&#xD;
             stable INR between 2.5-3.5 is permitted.&#xD;
&#xD;
          -  At least 4 weeks post-op from any major surgical procedure&#xD;
&#xD;
          -  Patients with asymptomatic brain metastases which have been treated with surgery or&#xD;
             radiation and demonstrate stability for ≥ 3 months will be allowed&#xD;
&#xD;
          -  Able to swallow tablets whole, without crushing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiologic disease progression while on treatment with letrozole and palbociclib in&#xD;
             the first line prior to enrollment&#xD;
&#xD;
          -  History of another invasive malignancy (other than non-melanoma skin cancer or&#xD;
             curatively treated in situ carcinoma) with evidence of disease within the past 3 years&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographic condition that would&#xD;
             potentially hinder compliance with the study protocol&#xD;
&#xD;
          -  Known untreated or symptomatic brain metastasis&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95mmHg) despite&#xD;
             medical treatment. Patients with a history of hypertension are allowed provided blood&#xD;
             pressure is controlled by anti-hypertensive treatment.&#xD;
&#xD;
          -  Clinically significant heart disease as evidenced by myocardial infarction or arterial&#xD;
             thrombotic event within the past 6 months, severe or unstable angina, or New York&#xD;
             Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction&#xD;
             measurement of &lt; 50% at baseline&#xD;
&#xD;
          -  Screening ECG with rate-corrected (using Friderica's correction) QT interval (QTcF) of&#xD;
             &gt;480 msec or a history of cardiac arrythmias&#xD;
&#xD;
          -  Refractory nausea and vomiting, requirement for parenteral hydration and/or nutrition,&#xD;
             drainage gastrostomy tube, malabsorption, external biliary shunt, or significant small&#xD;
             bowel resection that would preclude adequate study drug absorption&#xD;
&#xD;
          -  Is pregnant or breastfeeding, and/or expecting to conceive within the projected&#xD;
             duration of the trial, starting with the pre-screening or screening visit through 120&#xD;
             days after the last dose of trial treatment.&#xD;
&#xD;
          -  Current use of estrogen or progesterone products including intrauterine and&#xD;
             implantable contraceptive devices.&#xD;
&#xD;
          -  Anticipated or ongoing administration of anti-cancer therapies other than those&#xD;
             administered in this study&#xD;
&#xD;
          -  Active Hepatitis B (HBsAg positive or hepatitis B virus DNA≥1×10^3 copy/ml) or&#xD;
             Hepatitis C (e.g., HCV RNA [qualitative] is detected).&#xD;
&#xD;
          -  Use of any prescription medication during the prior 28 days of first onapristone&#xD;
             dosing that the investigator judges is likely to interfere with onapristone activity;&#xD;
             specifically, strong inhibitors or inducers, or sensitive substrates of cytochrome&#xD;
             P450 CYP3A4.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Komal Jhaveri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Komal Jhaveri, MD</last_name>
    <phone>646-888-5145</phone>
    <email>jhaverik@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joshua Drago, MD</last_name>
    <phone>646-888-6971</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Komal Jhaveri, MD</last_name>
      <phone>646-888-5145</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Limited protocol activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Komal Jhaveri, MD</last_name>
      <phone>646-888-5145</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (Limited Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Komal Jhaveri, MD</last_name>
      <phone>646-888-5145</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Komal Jhaveri, MD</last_name>
      <phone>646-888-5145</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Limited protocol activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Komal Jhaveri, MD</last_name>
      <phone>646-888-5145</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Komal Jhaveri, MD</last_name>
      <phone>646-888-5145</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Komal Jhaveri, MD</last_name>
      <phone>646-888-5145</phone>
    </contact>
    <investigator>
      <last_name>Komal Jhaveri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ER+, PR+, HER2</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Palbociclib</keyword>
  <keyword>Onapristone</keyword>
  <keyword>21-194</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Onapristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

